Azithromycin

C. diff Risk

Medium

Oral Bioavailability

Moderate

Spectrum Of Activity

Dosing

Serious Infection10 mg/kg/dose IV/PO daily

Serious Infection10 mg/kg/dose IV/PO daily

Serious Infection: 1-5 MonthsSerious Infection: ≥6 Months10 mg/kg/dose IV/PO every 24 hr x 5 days10 mg/kg/dose IV/PO x 1
(max 500 mg/dose)
then
5 mg/kg/dose IV/PO every 24 hr x 4 doses
(max 250 mg/dose)

Respiratory Infection(not-hospitalized)
500mg PO/IV on day 1 then 250mg daily x 4 days

Respiratory Infection(hospitalized)
500 mg PO/IV daily x 5 days

non-respiratory infection
500mg PO/IV daily

No adjustment required

General Information

Very high tissue penetration and concentration intracellularly means in vivo activity may not be predicted by in vitro testing - e.g. Salmonella species.

  • GI effects

  • Allergic reaction

  • Prolongation of QTc interval. Association with increased cardiovascular mortality in observational studies.

  • Community acquired pneumonia

  • Pertussis

  • Upper respiratory tract infections

  • Chlamidial infections

  • Mycobacterial infections

  • Mycobacterium avium complex (MAC) prophylaxis in HIV patients

Lab

  • Peridoc LFTs with prolonged use

Clinical

  • Monitor QTc in patients with increased risk

  • GI side effects

  • Other drugs that prolong QTc

  • Increases cyclosporine levels

  • May increase digoxin levels

  • Use with Statins increases risk of rhabdomyolysis

Antimicrobial class: Macrolide

Pregnancy category: B

Average serum half life: 68 hours

Biliary penetration: Therapeutic

CSF penetration: Poor

Lung penetration: Therapeutic

Urine penetration: Poor